Profil
Alain Bernard is currently the Chief Technology Officer at VectivBio Holding AG since 2019.
Prior to this, he worked as the Head-Global Biotech Process Development at R-Pharm JSC from 2017 to 2019, Vice President-Biopharmaceutical Process Sciences at UCB SA from 2006 to 2016, and Director-Biotech Process Development at Merck Serono SA from 2002 to 2006.
Dr. Bernard holds a doctorate degree from the Massachusetts Institute of Technology.
Tidigare kända positioner av Alain Bernard
| Företag | Position | Slut |
|---|---|---|
R-Pharm JSC
R-Pharm JSC BiotechnologyHealth Technology Engages in research, development and manufacturing of medicines & wholesales medical supplies | Företagsledare/Principal | 2019-07-01 |
| UCB | Företagsledare/Principal | 2016-01-01 |
Merck Serono SA
Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Företagsledare/Principal | 2006-11-01 |
| VECTIVBIO HOLDING AG | Teknisk/Vetenskaplig/F&U Direktör | - |
Alain Bernards utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
UCB SA
UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Merck Serono SA
Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Health Technology |
R-Pharm JSC
R-Pharm JSC BiotechnologyHealth Technology Engages in research, development and manufacturing of medicines & wholesales medical supplies | Health Technology |
VectivBio Holding AG
VectivBio Holding AG Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for rare diseases | Health Technology |
















